Loading
SIRPA (Tyrosine-protein phosphatase non-receptor type substrate 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Colorectal cancer, Non-Hodgkin lymphoma and 1 more.
Immunoglobulin-like cell surface receptor for CD47. Acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. Supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment.
IntOGen calls it a driver in 5 cohorts (4 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia, Cervical Squamous Cell Carcinoma, Colorectal Adenocarcinoma, High-Grade Glioma, NOS, Malignant Lymphoma.
In plain words · SIRPA (Tyrosine-protein phosphatase non-receptor type substrate 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Colorectal cancer, Non-Hodgkin lymphoma and 1 more.
SIRPA (Tyrosine-protein phosphatase non-receptor type substrate 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Colorectal cancer, Non-Hodgkin lymphoma and 1 more.
Immunoglobulin-like cell surface receptor for CD47. Acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane.
No product in this corpus aims at SIRPA yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 1997. Earliest sequence paper UniProt cites for the protein: Yamao et al, Biochem. Biophys. Res. Commun, 1997, "Mouse and human SHPS-1: molecular cloning of cDNAs and chromosomal localization of genes". Source.
Sources: HGNC HGNC:9662 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P78324 (protein name, function text, keywords and locations (REST API)); IntOGen SIRPA (driver in 5 cohorts (Act 4, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Immunoglobulin-like cell surface receptor for CD47. Acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. Supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment. May play a key role in intracellular signalling during synaptogenesis and in synaptic function. Involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin. Mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. Location: Membrane (UniProt). Locus 20p13 (HGNC).
Query for this target: (TITLE:"SIRPA" OR ABSTRACT:"SIRPA" OR TITLE:"signal regulatory protein alpha" OR ABSTRACT:"signal regulatory protein alpha" OR TITLE:"Tyrosine-protein phosphatase non-receptor type substrate 1" OR ABSTRACT:"Tyrosine-protein phosphatase non-receptor type substrate 1" OR TITLE:"SHPS1" OR ABSTRACT:"SHPS1" OR TITLE:"MYD-1" OR ABSTRACT:"MYD-1" OR TITLE:"P84" OR ABSTRACT:"P84") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SIRPA, not a curated reading list.
Shares Siglec-10, Checkpoint (two meanings).
Shares Checkpoint (two meanings), IntOGen, Non-Hodgkin lymphoma (all types).
Shares Checkpoint (two meanings), IntOGen, Non-Hodgkin lymphoma (all types), Colorectal cancer.
Shares Checkpoint (two meanings), IntOGen, Colorectal cancer.
Shares Checkpoint (two meanings), IntOGen.